Navigation Links
CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
Date:9/17/2007

uidance for establishing cerebral tissue oxygen saturation threshold values in various medical situations. Studies with this funding are planned to begin within the next two months."

To date, CASMED has been awarded six SBIR grants totaling $5 million from NINDS of the National Institutes of Health to support the development and commercialization of its absolute cerebral oximeter.

About the FORE-SIGHT Absolute Cerebral Oximeter

CASMED's initial market focus for the FORE-SIGHT product is on high-risk cardiovascular surgeries, of which there are about 700,000 performed each year in the U.S. Additional market opportunities include a broad range of general surgical procedures and post-operative and critical care settings. Protecting the brain from low oxygen levels during these procedures is an important goal of every surgical team because the brain is highly vulnerable to oxygen deprivation. At normal body temperatures, damage to brain cells due to lack of oxygen can occur after just a few seconds. The FORE-SIGHT Cerebral Oximeter provides new information that allows clinicians to monitor and respond to instances of brain tissue oxygen deprivation before damage to the brain occurs.

About CASMED(R)

Founded in 1984, CAS Medical Systems, Inc. is dedicated to the design and manufacture of innovative technologies and products vital to patient care in the most challenging clinical environments. Its current product lines include blood pressure measurement technology, vital signs monitoring equipment, blood pressure cuffs, apnea monitoring equipment and products for neonatal intensive care. With a reputation for the highest quality products available in the markets it serves, CASMED products are used by clinicians worldwide.

For further information regarding CAS Medical Systems, Inc., visit the Company's website at http://www.casmed.com.

Company Contacts

CAS Medical Systems, Inc
'/>"/>

SOURCE CAS Medical Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Dec. 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ... from the pivotal Phase 2b 003-A1 study, known ... well-tolerated in heavily pre-treated relapsed and refractory multiple ... the ASH/ASCO Joint Symposium at the 51st annual ... in New Orleans. Enrollment in this trial is ...
(Date:12/6/2009)... new study provides welcome news for patients with a ... , The condition is estimated to impact 62,000 Canadians ... abnormal clot forms in a vein and restricts the ... cases, the clot may detach from its point of ... causing a potentially fatal condition known as a pulmonary ...
(Date:12/6/2009)... says dangerous substances such as asbestos have been found in toys ... ... (PRWEB) December 6, 2009 -- As parents shop for children,s toys ... recalls due to lead paint or asbestos contamination, says a New ... emergency rooms each year due to toy-related injuries,” says Joseph W. ...
(Date:12/5/2009)... What: Cuts for a Cause ,, Why: ... and other terminal illnesses affecting children. All proceeds from each ... Research Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, ... in Falls Church for all guests. Hoa Lai, a DJ ...
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative ... Research presented today at the 51st Annual Meeting ... new treatment options and improved diagnostic methods for ... leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... Physicians with Flexibility and Control for Lead ... ... SPNC ) today announced the availability of the new LLD,EZ Lead ... leads. The LLD EZ enables physicians to secure,the entire lead creating traction ...
... WELLINGTON, Fla., May 15 The Quantum Group,Inc. ... announced today,through its subsidiary, Renaissance Health Systems, Inc. ... to centralize information pertaining,to the top five (5) ... and secure,HIPAA compliant environment. In addition to providing ...
... grant program will fund a pilot study in Vietnam ... for getting type 2 diabetes and promote a program ... , The National Hospital of Endocrinology (NHOE) will launch ... questionnaires (1) , the investigators hope to identify people ...
... Inc., the developer,of the first and only flexible ... surgery, today announced the closing of a $25 ... healthcare venture capital,and private equity firm, led the ... Stata Venture Partners, 3i, Argonaut,Ventures, ESI, Gainesborough Investments, ...
... Enables Creation of Global Unified Worklist ... or System, SEATTLE, May 15 Compressus, ... Seattle Radiologists, APC, of,Seattle, announced today an agreement ... imaging and data management systems.,The implementation, which will ...
... wealth of healthcare and medical device experience to board ... of ... developer,of the first and only flexible CO2 laser scalpel enabling new ... been,elected to the company,s board of directors. Suennen, co-founder and,managing member ...
Other Medicine News:Health News:Spectranetics Introduces New Device for Removal of Non-Functional and Infected Cardiac Leads 2Health News:Spectranetics Introduces New Device for Removal of Non-Functional and Infected Cardiac Leads 3Health News:The Quantum Group Announces Web-Based Portal for Physicians 2Health News:The Quantum Group Announces Web-Based Portal for Physicians 3Health News:International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam 2Health News:OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration 2Health News:OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration 3Health News:Compressus Announces Seattle Radiologists Interoperability Implementation 2Health News:Compressus Announces Seattle Radiologists Interoperability Implementation 3Health News:Lisa M. Suennen Joins OmniGuide(R) Board of Directors 2
(Date:12/4/2009)... (NYSE: WPI ), a leading global specialty ... Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with ... market its 8mg ramelteon tablets prior to the expiration ... Watson,s 8mg ramelteon tablet product is a generic ...
(Date:12/4/2009)... disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), ... comorbidities reported to occur more often in people ... versus those without an epilepsy diagnosis, according to ... U.S. ,, Findings from " CNS-Related Comorbidities in ...
(Date:12/3/2009)... (Nasdaq: PCYC ), a biopharmaceutical company focused on ... treatment of immune mediated diseases and cancer, today announced ... on, Tuesday, December 8, 2009 at 11:00am Eastern Time ... clinical data regarding its HDAC Program (PCI-24781) and its ...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 1Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 2Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 4Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 5Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 6Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 7Young Ballerinas May Face Heart Bone Risks 47452 1Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 1Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 2Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 3
... Jan. 7 ImQuest Life Sciences announced today the ... and Drug Administration to initiate human clinical trials for ... their Phase 1 studies in the first quarter of ... HIV which primarily acts as a nonnucleoside reverse transcriptase ...
... U.S., U.K. and China TrialsSAN DIEGO, Jan. 7 ... liver disease, today announced patient enrollment has begun for ... will study the Extracorporeal Liver Assist Device (ELAD) as ... under three protocols. The study is open for enrollment ...
Other Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3
ISI Alumi-Hand is the safe, sterile, ready-to-use ,surgical hand immobilizer....
ISI DuraHand is the reusable, easy to sterilize surgical hand immobilizer....
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
Medicine Products: